The researchers believe that their prototype could be the basis of a portable, point-of-care testing platform that would enable rapid testing anywhere.
Under the emergency use authorization, the rapid antigen test can be used in both symptomatic and asymptomatic individuals, and in children as well as adults.
Epoc NXS Host with the Epoc Blood Analysis System provides color-coded test results quickly and simplifies and streamlines the blood gas testing process.
The firm said its test fits in the palm of a hand and delivers results in 30 minutes by detecting bacterial nucleic acid in throat, nasal, or nasopharyngeal swabs.
The company received $26.1 million from the National Institutes of Health and the Biomedical Advanced Research and Development Authority to develop the test.
Some insiders emphasize the importance of doing rapid turnaround testing of asymptomatic people, while others contend lab tests ought to be the modality of choice.
Wyss Institute said iQ Group Global will integrate its affinity-based technology with a biosensor platform that includes organic thin-film transistors to enhance electrical signals.
The firms said that their hand-held digital test would require minimal training and be performed at the point of care without the need of a laboratory.
The German biotech firm said its lateral flow blood test does not detect subclinical HPV infection but picks up on HPV-induced cancers and pre-cancers.
The loop-mediated isothermal amplification test runs on a battery-powered device to provide self-testing individuals with results in approximately 30 minutes.